FR2921935B1 - Procede de criblage de composes utilisables pour le traitement de troubles respiratoires - Google Patents

Procede de criblage de composes utilisables pour le traitement de troubles respiratoires

Info

Publication number
FR2921935B1
FR2921935B1 FR0706999A FR0706999A FR2921935B1 FR 2921935 B1 FR2921935 B1 FR 2921935B1 FR 0706999 A FR0706999 A FR 0706999A FR 0706999 A FR0706999 A FR 0706999A FR 2921935 B1 FR2921935 B1 FR 2921935B1
Authority
FR
France
Prior art keywords
respiratory disorders
screening compounds
treating respiratory
functional activity
test molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0706999A
Other languages
English (en)
Other versions
FR2921935A1 (fr
Inventor
Jacques Barhanin
Christian Gestreau
Richard Warth
Dirk Heitzmann
Jorg Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paul Cezanne Aix Marseille III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paul Cezanne Aix Marseille III filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0706999A priority Critical patent/FR2921935B1/fr
Priority to US12/681,452 priority patent/US8119362B2/en
Priority to EP08865189A priority patent/EP2193377A2/fr
Priority to CA2700875A priority patent/CA2700875A1/fr
Priority to PCT/FR2008/001391 priority patent/WO2009080910A2/fr
Priority to JP2010527497A priority patent/JP2011501657A/ja
Publication of FR2921935A1 publication Critical patent/FR2921935A1/fr
Application granted granted Critical
Publication of FR2921935B1 publication Critical patent/FR2921935B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à l'utilisation d'un procédé de criblage pour l'identification de molécules candidates utilisables pour le traitement de troubles respiratoires chez un mammifère, ledit procédé de criblage comprenant une étape consistant à déterminer si l'activité fonctionnelle d'un polypeptide TASK-2 en présence d'une molécule test est diminuée ou supprimée par rapport à l'activité fonctionnelle dudit polypeptide TASK-2 en l'absence de ladite molécule test, la molécule test étant considérée comme étant une molécule candidate lorsqu'elle diminue ou supprime ladite activité fonctionnelle.
FR0706999A 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires Expired - Fee Related FR2921935B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0706999A FR2921935B1 (fr) 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires
US12/681,452 US8119362B2 (en) 2007-10-05 2008-10-03 Method of screening for compounds that can be used for the treatment of respiratory conditions
EP08865189A EP2193377A2 (fr) 2007-10-05 2008-10-03 Procédé de criblage de composés utilisables pour le traitement de troubles respiratoires
CA2700875A CA2700875A1 (fr) 2007-10-05 2008-10-03 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires
PCT/FR2008/001391 WO2009080910A2 (fr) 2007-10-05 2008-10-03 Procédé de criblage de composés utilisables pour le traitement de troubles respiratoires
JP2010527497A JP2011501657A (ja) 2007-10-05 2008-10-03 呼吸器系疾患の治療に使用することができる化合物をスクリーニングする方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706999A FR2921935B1 (fr) 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires

Publications (2)

Publication Number Publication Date
FR2921935A1 FR2921935A1 (fr) 2009-04-10
FR2921935B1 true FR2921935B1 (fr) 2011-10-28

Family

ID=39401127

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0706999A Expired - Fee Related FR2921935B1 (fr) 2007-10-05 2007-10-05 Procede de criblage de composes utilisables pour le traitement de troubles respiratoires

Country Status (6)

Country Link
US (1) US8119362B2 (fr)
EP (1) EP2193377A2 (fr)
JP (1) JP2011501657A (fr)
CA (1) CA2700875A1 (fr)
FR (1) FR2921935B1 (fr)
WO (1) WO2009080910A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202017007491U1 (de) * 2016-12-02 2022-01-07 Sophion Bioscience A/S Dichtungsverstärker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044981A2 (fr) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Inhibition a mediation d'interference d'arn de l'expression genetique a l'aide d'acide nucleique d'interference court (sina)
WO2005054867A2 (fr) * 2003-11-25 2005-06-16 Bayer Healthcare Ag Diagnostics et therapeutique pour maladies associees au canal potassique de la sous-famille k, membre 5 (kcnk5)
US20050234000A1 (en) * 2003-12-12 2005-10-20 Mitchell Gordon S SiRNA delivery into mammalian nerve cells
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
EP2193377A2 (fr) 2010-06-09
FR2921935A1 (fr) 2009-04-10
WO2009080910A3 (fr) 2009-09-03
JP2011501657A (ja) 2011-01-13
WO2009080910A2 (fr) 2009-07-02
US20110014642A1 (en) 2011-01-20
US8119362B2 (en) 2012-02-21
CA2700875A1 (fr) 2009-07-02
WO2009080910A8 (fr) 2010-04-29

Similar Documents

Publication Publication Date Title
ATE516262T1 (de) Derivate von 4-(2-amino-1-hydroxyethyl)phenol als agonisten des beta-2-adrenergen rezeptors
Willmann et al. Impairment of prostate cancer cell growth by a selective and reversible lysine‐specific demethylase 1 inhibitor
JP2017524130A5 (fr)
Shoubridge et al. IQSEC2 mutation update and review of the female‐specific phenotype spectrum including intellectual disability and epilepsy
EP3899022A4 (fr) Système de test de diagnostic basé sur l'impédance portatif pour la détection d'analytes
ATE531695T1 (de) Derivate von 4-(2-amino-1-hydroxyethyl)phenol als agonisten des beta2-adrenergen rezeptors
WO2018049268A8 (fr) Biomarqueurs pour le diagnostic et la caractérisation de la maladie d'alzheimer
WO2012024535A3 (fr) Procédés de détermination de la présence ou du risque de développement de la dystrophie facio-scapulo-humérale (fshd)
Hariono et al. Arylamide as potential selective inhibitor for matrix metalloproteinase 9 (MMP9): design, synthesis, biological evaluation, and molecular modeling
WO2009003905A3 (fr) Procédé pronostique pour déterminer le caractère approprié d'un traitement biopharmaceutique
Schmitz et al. Increased monocyte adhesion by endothelial expression of VCAM-1 missense variation in vitro
EP2909628A4 (fr) Puce multiplexée volumétrique à diagramme à barres (puce v) pour l'analyse quantitative de biomarqueurs et/ou d'analytes hors laboratoire
WO2012042541A3 (fr) Procédé de prédiction et de modélisation d'une activité anti-psychotique à l'aide d'un modèle de criblage virtuel
Ekins et al. Molecular characterization of CYP2B6 substrates
Lima et al. Genetic and epigenetic control of ACE2 expression and its possible role in COVID‐19
Gehling et al. Design and synthesis of styrenylcyclopropylamine LSD1 inhibitors
WO2005000875A3 (fr) Compositions et procedes contenant un ligand de chemerinr
FR2936255B1 (fr) Modulateurs de fzd2 dans le traitement de l'alopecie
Dichiara et al. Designing drugs optimized for both blood–brain barrier permeation and intra-cerebral partition
Zahr et al. Renal protection by atorvastatin in a murine model of sickle cell nephropathy
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
JP2007523166A5 (fr)
Bennet et al. Pleiotropy in the presence of allelic heterogeneity: alternative genetic models for the influence of APOE on serum LDL, CSF amyloid-β42, and dementia
ATE452885T1 (de) Aminoarylsulfonamidderivate als funktionelle 5- ht6-liganden

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150630